Cerus appoints Andrew Gomperts CBO
This article was originally published in Scrip
Executive Summary
Biomedical products company Cerus Corporation has appointed Andrew Gomperts chief business officer and vice-president of business development and marketing. He most recently served as head of corporate and business development at Sangart, and has prior experience at Idealab, Prometheus Laboratories and McKinsey & Company.
You may also be interested in...
Almirall launches Constella in six European markets
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira raises $35m in series B
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis ups public offering to $240m
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.